L2S2 and TTP announce CoolMate joint technology collaboration

Image

TTP and L2S2 have jointly accelerated the development of CoolMate, an engagement solution that enables patients to self-manage their sensitive biologics at home, bringing them freedom and convenience in a safe and controlled manner.

Patients often struggle with self-administering biologic medicines due to simple misunderstanding, forgetfulness, disorganization, mistrust, too many medications, worry, and even depression. Digital interventions and support tools which aim to address these factors have had limited effectiveness to date due to their inability to adapt to user variability whilst also rapidly offering scale.

TTPCoolMate
The connected CoolMate system can manage autoinjectors inside TTP’s smart enclosure and patient-centric mobile app in combination with the L2S2-regulated cloud-based platform (MMDC). The system adapts and deploys behavioural design techniques, accommodating individual patients’ needs, preferences, and routines.

CoolMate is capable of:

  • Generating Patient Reported Outcomes (PROs) and engagement data.
  • Patient guidance, education, and reassurance (e.g., push notifications).
  • Rapid customizability and scalability.
  • Medication batch traceability (NFC/RFID).
  • Electronic Medical Records (EMR) system and workflow integration, streamlining clinical adoption.
  • Medication stock forecasting and responding to unexpected patient-related events.
  • Inclusion in clinical trials or for rapid real-world R&D testing by Contract Research Organizations (CROs) and pharmaceutical companies.
CoolMate speaks to L2S2 and TTP’s understanding of deploying medical devices into clinical systems through both specialized hardware and software, with an approach that is friendly for all stakeholders.

Located in Cambridge, UK, TTP plc has been operational since 1987. They are currently an innovation leader in the end-to-end development of connected medical devices and patient-centric design. With strong partnerships across the Pharmaceutical and MedTech sectors, they operate as an independent technology company where scientists, engineers, and designers collaborate to invent and develop new products and technologies.

Contact TTP: digitalhealth@ttp.com

MMDC, developed by Cambridge-based L2S2 Ltd, is a scalable ISO13485-compliant medical data and analytics SaaS platform that is embedded into the highly guarded healthcare IT ecosystem. It has rapid development tools for regulated healthcare products and provides de-risked, compliant data and product life-cycle management.  MMDC’s unique architecture permits it to collect remote patient data, analyse this data, and present it to clinicians, whereupon it can be integrated directly into patient record systems.

Contact us

Let's realise your ideas

Email us:
contact@l2s2.com
Call us:
+44 1223 234 550
Visit us:
L2S2
2a Oakington Business Park
Cambridge
CB24 3DQ

    Image

    © 2022 L2S2 Ltd. All Rights Reserved

    Privacy Policy | GDPR | ISO 13485:2016 | ISO 27001:2013 | Cyber Essentials | NHS DSP Toolkit | OWASP | HSCN | Mobile Apps